Journal of Capital Medical University ›› 2001, Vol. 22 ›› Issue (2): 119-122.

• 论著 • Previous Articles     Next Articles

The 4G/5G Polymorphism of the Plasminogen Activator Inhibitor-1 Gene in Patients with Coronary Heart Disease

Fu Yan1, Wang Xudong1, Zhai Yanling1, Fan Zheng2, Yang Ling1, Zhu Yuqing1, Qi Yahui2, Zhao Xiangyin1   

  1. 1. Emergency Department, Beijing Tongren Hospital, Affiliate of Capital University of Medical Sciences;2. Laboratory Centre, Capital University of Medical Sciences
  • Received:2001-01-03 Revised:1900-01-01 Online:2001-04-15 Published:2001-04-15

Abstract: WT5BZ]To investigate the relationship between 4G/5G polymorphism of the plasminogen activator inhibitor-1(PAI-1)gene and coronary heart disease(CHD), genotype at this polymorphism was determined in 123 cases with CHD and 172 controls by polymerase chain reaction using the allele specific primers. Plasma PAI-1 antigen level, PAI activity, cholesterol and triglyceride were measured and body mass index was calculated from all the subjects. The group of CHD had a high number of homozygotes for the deleted allele(4G/4G)of the PAI-1 gene compared with the control(47.2% vs 22.1%, P< 0.05). Mean plasma PAI-1 antigen level and PAI activity varied significantly among the 3 genotypes, being higher in 4G/4G subjects than in 5G/5G subjects 〔(40.87±0.99)μg/L〕 vs 〔(38.14±1.0)μg/L〕, 〔(750±350)U/L〕 vs(650±270)U/L, P<0.05). The PAI-1 4G/5G polymorphism correlated with PAI-1 antigen level to some extent accounts for the development of CHD.

Key words: coronary heart disease, plasminogen activator inhibitor-1, gene polymorphism

CLC Number: